Exploring the oncogenic multifaced role of MUC1 in pancreatic tumor biology and the impact of its alterations, in terms of expression as well as post-translational modification, in PDAC onset and progression, this review promptly considers MUC1 a potential novel target for innovative drugs in PDAC therapy. Here, MUC1 is linked to pancreatic neoplasm.